Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Biogen Option Volume And Open Interest Over Last 30 Days Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan.

Biogen Call and Put Volume: 30-Day Overview Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and ...

Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) and Idec (classic blood cancer drug Rituxan). The firm expanded its neurology portfolio ...

The table is limited by our hospital pharmacy's formulary; however, our purpose was to update the current literature. The table is intended for use as a guide when medications labeled for ...

Elan Biogen Idec) will be discussed. In addition, the possibility that other viruses use a similar cellular apparatus to invade host cells will be discussed. Figure 2: Identification of the 5 ...

High-dose vitamin D supplementation reduces disease activity in clinically isolated syndrome typical of MS, results of a ...

Search for a state or federal candidate to see the donors and industries that support them.

It was five years ago today that then-Gov. Charlie Baker declared a State of Emergency in Massachusetts due to the rapidly ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...